

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Nephrology

Manuscript NO: 87649

Title: Antihypertensive prescribing patterns in non-dialysis dependent chronic kidney

disease: Findings from the Salford Kidney Study

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05821524 Position: Editorial Board

Academic degree: FACP, FASN, FEBS, FRCP, MBChB, MD

Professional title: Assistant Professor, Consultant Physician-Scientist

Reviewer's Country/Territory: Iraq

Author's Country/Territory: United Kingdom

Manuscript submission date: 2023-08-20

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-08-28 12:54

Reviewer performed review: 2023-09-01 12:10

Review time: 3 Days and 23 Hours

	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [] Grade B: Good [Y] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of	[] Grade A: Excellent [] Grade B: Good [Y] Grade C: Fair
this manuscript	[] Grade D: No creativity or innovation



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	[] Grade A: Excellent [] Grade B: Good [Y] Grade C: Fair [] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y] Yes [] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Thanks to all authors for such an effort. I have the following points: 1. Authors used the terms ACEi, ARBS, and RABs in the text and tables. For the reader, it seems they are using them interchangeably, although the numbers on the tables are different and not additive. It would be better to unify the terms in a group with a crystal-clear definition for easy readability, like (RAAS blockade). Terms and practice are not similar in all countries; thus, it would be better to use consensus terms. 2. Authors emphasized the notion by most guidelines that NDCCBs are the preferred group of CCBs especially in. The results revealed that DCCBs are the 3rd option even in patients with proteinuria. This needs to be discussed. Is it deviation from the guidelines, why there is such a trend, and what are the possible factors? 3. Authors should mention that GFR analysis was not made to all participants as a limitation of the study.